SHANDONG BOAN BIOTECH.H 1 (UJ9) - Total Liabilities
Based on the latest financial reports, SHANDONG BOAN BIOTECH.H 1 (UJ9) has total liabilities worth €1.39 Billion EUR (≈ $1.62 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check UJ9 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
SHANDONG BOAN BIOTECH.H 1 - Total Liabilities Trend (2021–2025)
This chart illustrates how SHANDONG BOAN BIOTECH.H 1's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of SHANDONG BOAN BIOTECH.H 1.
SHANDONG BOAN BIOTECH.H 1 Competitors by Total Liabilities
The table below lists competitors of SHANDONG BOAN BIOTECH.H 1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Linedata Services S.A.
PA:LIN
|
France | €190.30 Million |
|
AG Mortgage Investment Trust Inc
NYSE:MITT
|
USA | $7.74 Billion |
|
ZongTai Real Estate Development Co Ltd
TW:3056
|
Taiwan | NT$6.45 Billion |
|
Stic Investments Inc
KO:026890
|
Korea | ₩49.69 Billion |
|
Great China Metal Industry Co Ltd
TW:9905
|
Taiwan | NT$3.49 Billion |
|
Teixeira Duarte
LS:TDSA
|
Portugal | €1.20 Billion |
|
Pioneer Municipal High Income Trust
NYSE:MHI
|
USA | $59.28 Million |
|
Comstock Holding Companies Inc
NASDAQ:CHCI
|
USA | $10.98 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down SHANDONG BOAN BIOTECH.H 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See UJ9 net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SHANDONG BOAN BIOTECH.H 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SHANDONG BOAN BIOTECH.H 1 (2021–2025)
The table below shows the annual total liabilities of SHANDONG BOAN BIOTECH.H 1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.39 Billion ≈ $1.62 Billion |
+14.79% |
| 2024-12-31 | €1.21 Billion ≈ $1.41 Billion |
+20.30% |
| 2023-12-31 | €1.00 Billion ≈ $1.17 Billion |
+27.97% |
| 2022-12-31 | €784.18 Million ≈ $916.79 Million |
+41.32% |
| 2021-12-31 | €554.92 Million ≈ $648.76 Million |
-- |
About SHANDONG BOAN BIOTECH.H 1
Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, … Read more